Pharmaceutical Technology
MAY 24, 2023
Every major pharma company is now involved in CGT development which has resulted in the approval of 28 therapies by the FDA thereby making CGT no longer a niche category of therapies. This is due to major differences throughout the clinical supply chain in both requirements and management practices.
The Pharma Data
SEPTEMBER 14, 2020
Supply chain uncertainty is a challenge every clinical supply chain manager wrestles with – stemming from increasing product demand and quality, the growing complexity of clinical trial designs and a lack of visibility in the supply chain.
Pharmaceutical Technology
MARCH 20, 2023
Africa has considerable advantages and opportunities for trialling investigational medicinal products that, if pharma companies can correctly harness, will turn the continent into a superpower for clinical trials. In addition, the time-savings offered by this facility in the clinical supply chain are considerable.
Expert insights. Personalized for you.
246 
Let's personalize your content